METHADONE ANONYMOUS--BEHAVIORAL THERAPY DEVELOPMENT
美沙酮匿名——行为疗法的发展
基本信息
- 批准号:6262557
- 负责人:
- 金额:$ 15.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-07-01 至 2004-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This therapy development study systematically introduces Methadone Anonymous (MA), a 12-step program, into conventional methadone maintenance treatment (MMT) in order to improve the outcome of rehabilitation. A number of problems are apparent in the care of MMT patients: high illicit drug use, lack of motivation for successful community integration, and HIV-risk behavior. These have shown relatively little improvement from the impact of program enhancements like traditional social services and pharmacologic adjuncts. Although the 12-Step model typically involves rejection of dependency-producing agents in treatment, our findings to date suggest that it can enhance the rehabilitation of methadone patients when it embodies the acceptance of methadone maintenance. This benefit can be understood on theoretical grounds on the basis of MA's peer support, voluntary affiliation, and spiritual orientation. However, the feasibility of this MA format has yet to be empirically demonstrated. This project is therefore framed as an R21 grant because it involves the introduction of an approach based on a theoretical model of treatment drawn from another field, namely, the AA maintenance-free approach. The study will proceed as a randomized group design, to include an MA Facilitation (MAF) treatment group (N = 96) and a comparison treatment-as-usual group (N = 96). The specific aims of this study are to: (1) prepare and evaluate an MAF manual for use by staff in the MAF condition; (2) assess the impact of MAF on outcome variables assessed at 6 months (e.g., illicit drug use, HIV risk behaviors); and (3) determine the impact of select patient characteristics (e.g., level of psychiatric distress, motivation) on change in MA attendance and illicit drug use among patients in the MAF condition. Consecutive admissions to the program will be randomly assigned to one of two treatment sites (standard methadone AT with MAF vs. standard MMT only). The development of the MA manual and results of this evaluation will provide pilot data for preparation of an RO1 proposal.
本研究系统地将美沙酮匿名治疗(Methadone Anonymous, MA)这一12步治疗方案引入到传统美沙酮维持治疗(MMT)中,以改善康复效果。在对MMT患者的护理中,有许多明显的问题:非法药物使用率高,缺乏成功融入社区的动机,以及艾滋病毒风险行为。从传统社会服务和药物辅助等项目的影响来看,这些方面的改善相对较小。虽然12步模型通常涉及对治疗中产生依赖的药物的拒绝,但我们迄今为止的研究结果表明,当它体现了对美沙酮维持的接受时,它可以增强美沙酮患者的康复。这种好处可以从MA的同伴支持、自愿归属和精神取向的理论基础上理解。然而,这种MA格式的可行性尚未得到实证证明。因此,该项目被列为R21拨款,因为它涉及引入一种基于另一个领域的治疗理论模型的方法,即AA免维护方法。该研究将采用随机分组设计,包括MA促进(MAF)治疗组(N = 96)和常规治疗组(N = 96)。这项研究的具体目的是:(1)编制和评估一份MAF手册,供在MAF条件下工作的员工使用;(2)评估MAF对6个月时评估的结果变量(如非法药物使用、艾滋病毒风险行为)的影响;(3)确定特定患者特征(如精神困扰水平、动机)对MAF患者MA出席率和非法药物使用变化的影响。该计划的连续入院将随机分配到两个治疗地点之一(标准美沙酮AT与MAF vs标准MMT)。MA手册的编制和这次评价的结果将为编制RO1提案提供试点数据。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARC GALANTER其他文献
MARC GALANTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARC GALANTER', 18)}}的其他基金
Network Therapy Development, Stage II with Buprenorphine
丁丙诺啡网络疗法开发第二阶段
- 批准号:
6974267 - 财政年份:2004
- 资助金额:
$ 15.69万 - 项目类别:
METHADONE ANONYMOUS--BEHAVIORAL THERAPY DEVELOPMENT
美沙酮匿名——行为疗法的发展
- 批准号:
6607507 - 财政年份:2001
- 资助金额:
$ 15.69万 - 项目类别:
METHADONE ANONYMOUS--BEHAVIORAL THERAPY DEVELOPMENT
美沙酮匿名——行为疗法的发展
- 批准号:
6515762 - 财政年份:2001
- 资助金额:
$ 15.69万 - 项目类别:
相似海外基金
The role of LILRB3-mediated immunomodulation on myeloid cells and exploration of new combination therapy for chronic inflammation and cancer
LILRB3介导的免疫调节对骨髓细胞的作用及慢性炎症和癌症联合治疗的探索
- 批准号:
24K18478 - 财政年份:2024
- 资助金额:
$ 15.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Fundamental research for the application of effective combination therapy of sarcomatoid kidney cancer to bone and soft tissue sarcoma
肉瘤样肾癌有效联合治疗骨软组织肉瘤应用的基础研究
- 批准号:
23K08696 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Combination therapy for renal cell carcinoma using oncolytic virus G47d
使用溶瘤病毒 G47d 联合治疗肾细胞癌
- 批准号:
23K08752 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of novel therapeutic target and mechanism for PARP inhibitor combination therapy
PARP抑制剂联合治疗的新治疗靶点和机制的鉴定
- 批准号:
23K08100 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanism-based combination therapy for cholangiocarcinoma
基于机制的胆管癌联合治疗
- 批准号:
10650049 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
MRI Study of Hydrogen Water and Minocycline Combination Therapy for Ischemic Stroke
氢水与米诺环素联合治疗缺血性中风的MRI研究
- 批准号:
10564735 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Development of novel combination therapy of chimeric antigen receptor T cells and HMG-CoA reductase inhibitors (statin)
嵌合抗原受体T细胞和HMG-CoA还原酶抑制剂(他汀类药物)的新型联合疗法的开发
- 批准号:
23K15306 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
治疗和预防肺淋巴管平滑肌瘤病 (LAM) 和结节性硬化症 (TSC) 的新型联合疗法
- 批准号:
10697901 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Association between efficacy of Immuno-Oncology combination therapy for renal cell carcinoma and gut microbiota including fungi and viruses
肾细胞癌免疫肿瘤联合疗法的疗效与肠道微生物群(包括真菌和病毒)之间的关联
- 批准号:
23K08749 - 财政年份:2023
- 资助金额:
$ 15.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)